80 potentially relevant studies

70 excluded based on the titles/abstracts (laboratory studies, review articles, or irrelevant to the current analysis)

10 relevant studies for detailed evaluation

5 studies excluded
Pharmacokinetic-pharmacodynamic analysis (n= 1)
Without comparison (n= 1)
To determine the most appropriate oral dose of vernakalant for the prevention of AF recurrence postcardioversion (n= 1)
Atrial fibrillation after cardiac surgery (n= 1)
Pharmacokinetic of RSD 1235 and influence of CYP2D6 expression (n= 1)

5 RCTs included in meta-analysis